AI assistant
Twist Bioscience Corp — Director's Dealing 2018
Oct 30, 2018
31873_dirs_2018-10-30_c42aeb25-9fd0-4950-9aad-47ae1bad0573.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Twist Bioscience Corp (TWST)
CIK: 0001581280
Period of Report: 2018-10-30
Reporting Person: Ever Alpha Fund L.P. (10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 0 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series D Preferred Stock | $ | Common Stock (3294961) | Direct |
Footnotes
F1: The Series D Preferred Stock has no expiration date and will convert into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.
F2: Ever Glory Limited is the general partner of Ever Alpha Fund L.P. Ever Glory Limited is a wholly owned subsidiary of Guangfa Xinde Capital Management Limited. Guangfa Xinde Capital Management Limited is a wholly owned subsidiary of Guangfa Investment (Hong Kong) Company Limited. Guangfa Investment (Hong Kong) Company Limited is a wholly owned subsidiary of Guangfa Holding (Hong Kong) Corporation Limited.